A novel treatment for glioblastoma, consisting of a combination of an oncolytic virus, engineered to selectively infect and kill cancer cells, and type of a targeted immunotherapy called immune checkpoint inhibition, is showing promise, prolonging patient survival. Read the article from the University of Toronto here.